Labiotech.eu

News and Trends 17 Nov 2022

FundaMental Pharma launches with €10M to advance first-in-class neuroprotectant

FundaMental Pharma GmbH, a preclinical neuroscience company spun out of Heidelberg University in Germany, has launched with €10 million ($10.4 million) in seed financing. The funding was led by BioGeneration Ventures (BGV) and Thuja Capital, with participation from other investors, including coparion and High-Tech Gründerfonds (HTGF). Built on the research of Hilmar Bading and Jing […]

November 17, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 17 Nov 2022

New mitochondria study could pave way for disease treatments

Mitochondria, the ‘powerhouses of the cell,’ are important cellular structures that are vital for their role of generating energy. They constantly fuse together and split apart. They contain a small amount of genetic information, mitochondrial DNA (mtDNA). The mtDNA, organized into dot-like structures called nucleoids, also moves around inside the mitochondria. The method of distribution […]

November 17, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 16 Nov 2022

Discovery Park celebrates 10 years and plans to double jobs over the next decade

Plans to grow and double the number of people employed at Discovery Park, the UK’s biggest science and innovation center have been announced. The team behind its success shared the news as they celebrate a decade of delivering jobs and investment in the South East. Discovery Park marked the milestone by announcing its plans for […]

November 16, 2022 - 4 minutesmins - By Liza Laws

More News! 16 Nov 2022

Mineralys has positive topline results from trial evaluating treatment of hypertension

U.S.-based Mineralys Therapeutics, Inc., announced today (November 16) topline results from its phase 2 Target-HTN trial in individuals with uncontrolled and resistant hypertension. MLS-101, a highly selective investigational aldosterone synthase inhibitor, at doses of 50 mg and 100 mg once daily, met its primary endpoint with statistically significant and clinically meaningful reduction in systolic blood […]

November 16, 2022 - 4 minutesmins - By Liza Laws

Best in Biotech 16 Nov 2022

Six biotech stocks trading below cash right now

The biotech stock market is currently in a tough spot, with many companies facing suppressed valuations. We’ve listed six public companies trading with a market cap below their cash in hand. A range of factors are driving down company valuations in the public biotech market, such as soaring inflation, geopolitical instability and the threat of […]

November 16, 2022 - 6 minutesmins - By Jonathan Smith

News and Trends 16 Nov 2022

Foodtech company, Wilk, creates first cultured milk fat, cell-based yogurt

Israeli company, Wilk, has today (November 16) announced the successful development of the world’s first yogurt developed with cell-cultured milk fat. The company is a developer of cell-cultured human and animal milk and milk components and this hybrid product has been validated by external laboratories, which Wilk says confirms it meets the necessary chemical and […]

November 16, 2022 - 2 minutesmins - By Liza Laws

News and Trends 16 Nov 2022

Bio-Rad introduces pioneer antibody discovery platform for therapeutic development

Bio-Rad Laboratories Inc. yesterday (November 15) announced the launch of its Pioneer Platform, a new antibody discovery service specifically designed to develop biologic candidates. The Pioneer Platform features a phage display library engineered to include more than 200 billion unique sequences and capable of identifying high-affinity antibody candidates using Bio-Rad’s newly developed SpyDisplay selection technology. […]

November 16, 2022 - 2 minutesmins - By Liza Laws

News and Trends 16 Nov 2022

Ascletis’ monkeypox tablet receives IND approval from the FDA

A drug to treat monkeypox from Ascletis Pharma has had its investigational new drug (IND) application approved by the U.S Food and Drug Administration (FDA). The FDA made its decision based on the available data, which was 800 mg ASC10 taken twice a day, and Ascletis can now go ahead with a phase 1b clinical […]

November 16, 2022 - 3 minutesmins - By Liza Laws

News and Trends 16 Nov 2022

Enzymes could be key to understanding ‘origin of DNA errors’

Enzymes, critical to controlling how cells replicate in the human body, could be the very ingredient that encourages DNA to spontaneously mutate – causing potentially permanent genetic errors, according to new research from the University of Surrey in the U.K. Using quantum chemical calculations, researchers from Surrey’s Quantum Biology Doctoral Training Centre have found that […]

November 16, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 16 Nov 2022

Growth in UK cell and gene therapy sector continues

The Cell and Gene Therapy Catapult (CGT Catapult) has published its ninth annual U.K. cell and gene therapy Good Manufacturing Practice (GMP) manufacturing report, showing continued growth in the advanced therapy medicinal products (ATMP) UK manufacturing sector. This growth is across industry and academia, showing how the sector is responding to the operationalization and skills […]

November 16, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 16 Nov 2022

Kadans Science Partner to develop new London life sciences innovation facility

Kadans Science Partner and Canary Wharf Group (CWG) are developing a new innovation facility in London, U.K., to provide access to fully-fitted laboratories and space for developing life science companies. Kadans Science Partner is converting levels four and five, totalling 38,000 sq ft, at the BREEAM Outstanding 20 Water Street, into flexible, fully serviced CL2 […]

November 16, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 16 Nov 2022

Immutep announces efti clinical results for non-small cell lung cancer

Immutep Limited has revealed what it says are compelling new clinical data from its TACTI-002 all-comer PD-L1 phase II trial evaluating Immutep’s lead product candidate, eftilagimod alpha in combination with MSD’s (Merck and Co., Inc., Rahway, N.J., USA) anti-PD-1 therapy KEYTRUDA (pembrolizumab) in 114 patients with non-small cell lung cancer (NSCLC). The new data was […]

November 16, 2022 - 3 minutesmins - By Jim Cornall

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

FundaMental Pharma launches with €10M to advance first-in-class neuroprotectant

New mitochondria study could pave way for disease treatments

Discovery Park celebrates 10 years and plans to double jobs over the next decade

Mineralys has positive topline results from trial evaluating treatment of hypertension

Six biotech stocks trading below cash right now

Foodtech company, Wilk, creates first cultured milk fat, cell-based yogurt

Bio-Rad introduces pioneer antibody discovery platform for therapeutic development

Ascletis’ monkeypox tablet receives IND approval from the FDA

Enzymes could be key to understanding ‘origin of DNA errors’

Growth in UK cell and gene therapy sector continues

Kadans Science Partner to develop new London life sciences innovation facility

Immutep announces efti clinical results for non-small cell lung cancer

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!